ArticleInternational journal of clinical oncology2026
Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic options.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCombination therapy with enfortumab vedotin (EV) and pembrolizumab has shown superior overall survival (OS) compared to platinum-based chemotherapy in advanced urothelial carcinoma (UC). Given the expanding landscape of first-line treatments, understanding site-specific effectiveness is vital for developing individualized strategies.
methodsWe conducted a retrospective analysis of 225 patients with advanced UC treated between April 2009 and August 2024. Systemic therapy efficacy was assessed in relation to metastatic site, focusing on site-specific responses. Patients were classified into three treatment periods (chemotherapy period [April 2009-June 2017; P1], pembrolizumab period [July 2017-December 2020; P2], and avelumab and EV period [January 2021-August 2024; P3]). Within each period, patients were stratified by metastatic pattern-lymph node-only, liver, or other-and OS was analyzed accordingly.
resultsThe objective response rates for chemotherapy, pembrolizumab, avelumab, and EV were 41%, 23%, 20%, and 46%, respectively. Lymph node and pulmonary metastases exhibited favorable responses across all treatment modalities, whereas bone metastases consistently responded poorly. Notably, EV exhibited substantial activity against liver metastases. Median OS improved over successive treatment periods (P1: 14 months; P2: 16 months; P3: 26 months). However, patients with liver metastases experienced no meaningful OS improvement (P1: 9.5 months; P2: 9.2 months; P3: 8 months), with 54% of these patients not receiving EV.
conclusionsSequential therapies may offer a survival benefit in selected patients. EV plus pembrolizumab may be particularly beneficial in patients with rapidly progressive disease such as those with liver metastases, warranting further investigation in real-world settings.
Indexed as
Identifiers
41240181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.